Clinicopathologic features and molecular biomarkers as predictors of epidermal growth factor receptor gene mutation in non-small cell lung cancer patients
L Liu, X Xiong - Current Oncology, 2021 - mdpi.com
Lung cancer ranks first in the incidence and mortality of cancer in the world, of which more
than 80% are non-small cell lung cancer (NSCLC). The majority of NSCLC patients are in …
than 80% are non-small cell lung cancer (NSCLC). The majority of NSCLC patients are in …
The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in …
L Zhang, D Liu, L Li, D Pu, P Zhou, Y Jing, H Yu… - BMC cancer, 2017 - Springer
Background The roles of carcinoembryonic antigen (CEA), cytokeratin 19 fragments
(CYFRA21-1) and neuron-specific enolase (NSE) in metastases occurrence and poor …
(CYFRA21-1) and neuron-specific enolase (NSE) in metastases occurrence and poor …
Correlation between carcinoembryonic antigen (CEA) expression and EGFR mutations in non-small-cell lung cancer: a meta-analysis
T Gan, W An, Y Long, J Wang, H Zhang… - Clinical and Translational …, 2024 - Springer
Objectives The purpose of this meta-analysis was to investigate the relationship between
serum carcinoembryonic antigen (CEA) expression and epidermal growth factor receptor …
serum carcinoembryonic antigen (CEA) expression and epidermal growth factor receptor …
Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective …
O Arrieta, C Villarreal-Garza, L Martínez-Barrera… - BMC cancer, 2013 - Springer
Background High serum carcinoembryonic antigen (CEA) levels are an independent
prognostic factor for recurrence and survival in patients with non-small cell lung cancer …
prognostic factor for recurrence and survival in patients with non-small cell lung cancer …
Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
A Ono, T Takahashi, K Mori, H Akamatsu, T Shukuya… - BMC cancer, 2013 - Springer
Background Serum CYFRA 21–1 is one of the most important serum markers in the
diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma …
diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma …
Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in …
EY Romero-Ventosa, S Blanco-Prieto… - Springerplus, 2015 - Springer
The aim of this study has been to investigate the potential of serum biomarkers used in
clinical practice (CEA, CYFRA 21–1, SCC) together with the serum epidermal growth factor …
clinical practice (CEA, CYFRA 21–1, SCC) together with the serum epidermal growth factor …
[HTML][HTML] Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer
R Jiang, X Wang, K Li - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background The predictive and prognostic value of carcinoembryonic antigen (CEA),
cytokeratin-19 fragments (Cyfra21-1), squamous cell carcinoma antigen (SCCA) and neuron …
cytokeratin-19 fragments (Cyfra21-1), squamous cell carcinoma antigen (SCCA) and neuron …
Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma
Y Zhang, B Jin, M Shao, Y Dong, Y Lou, A Huang… - Tumor Biology, 2014 - Springer
For the detection of epidermal growth factor receptor (EGFR) mutations, tumor tissues may
not always be available. Not all the patients harboring EGFR mutation have a clinical …
not always be available. Not all the patients harboring EGFR mutation have a clinical …
Prognostic value of serum tumor markers in patients with stage III NSCLC treated with chemoradiotherapy
T Tokito, K Azuma, K Yamada, Y Naito, N Matsuo… - in vivo, 2019 - iv.iiarjournals.org
Background/Aim: Serum tumor markers such as carcinoembryonic antigen and cytokeratin
subunit 19 fragment are generally monitored in non-small cell lung cancer (NSCLC) patients …
subunit 19 fragment are generally monitored in non-small cell lung cancer (NSCLC) patients …
Erlotinib promotes endoplasmic reticulum stress-mediated injury in the intestinal epithelium
L Fan, L Hu, B Yang, X Fang, Z Gao, W Li, Y Sun… - Toxicology and applied …, 2014 - Elsevier
Erlotinib, a popular drug for treating non-small cell lung cancer (NSCLC), causes diarrhea in
approximately 55% of patients receiving this drug. In the present study, we found that …
approximately 55% of patients receiving this drug. In the present study, we found that …